Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

ClinicalTrials.gov ID: NCT01111552

Public ClinicalTrials.gov record NCT01111552. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 11, 2026, 3:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder

Study identification

NCT ID: NCT01111552
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Enrollment: 237 participants

Conditions and interventions

Conditions

Major Depressive Disorder (MDD)

Interventions

Aripiprazole Drug
Escitalopram Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 28, 2010
Primary completion: Sep 26, 2011
Completion: Sep 26, 2011
Last update posted: Oct 25, 2021

2010 – 2011

United States locations

U.S. sites: 20
U.S. states: 12
U.S. cities: 19

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35216	—
Not listed	Little Rock	Arkansas	72223	—
Not listed	Carson	California	90746	—
Not listed	Garden Grove	California	95231	—
Not listed	Imperial	California	92251	—
Not listed	Mission Viejo	California	92691	—
Not listed	Redlands	California	92374	—
Not listed	San Diego	California	92128	—
Not listed	Atlanta	Georgia	30308	—
Not listed	Atlanta	Georgia	30328	—
Not listed	Hoffman Estates	Illinois	60169	—
Not listed	Terre Haute	Indiana	47802	—
Not listed	Overland Park	Kansas	66211	—
Not listed	Prairie Village	Kansas	66206	—
Not listed	Wichita	Kansas	67207	—
Not listed	Baltimore	Maryland	21204	—
Not listed	New York	New York	10021	—
Not listed	Toledo	Ohio	43623	—
Not listed	Bartlett	Tennessee	38134	—
Not listed	Wichita Falls	Texas	76309	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01111552, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 25, 2021 · Synced May 11, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01111552 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →